1. Scrip
  2. >>Therapy Areas

GW's Epidiolex Epilepsy Data Paves Way For Cannabinoids

 
• By Emily Hayes

Safety and efficacy in study published in New England Journal of Medicine bode well for cannabinoid therapy Epidiolex, which is headed to FDA mid-year.

Epidolex

The positive reception of Phase III data for GW Pharmaceuticals PLC's cannabinoid therapy Epidiolex for Dravet syndrome, a severe type of pediatric epilepsy, in the New England Journal of Medicine is an important step for pharmaceutical-grade cannabinoids as a therapeutic option for neurological disorders as well as other diseases.

Derived from the marijuana plant, Epidiolex includes cannabidiol (CBD) but not the psychoactive tetrahydrocannabinol (THC). The drug is one of over 50 cannabinoids in any stage of development, according to Pharmaprojects. As of late 2016, candidates were in development for about 40 indications, including epilepsy, multiple sclerosis disorders, pain and schizophrenia (see sidebar)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.